Product Information
Registration Status: ActiveABILIFY ORAL SOLUTION 1MG/ML is approved to be sold in Singapore with effective from 2021-03-10. It is marketed by OTSUKA PHARMACEUTICALS (SINGAPORE) PTE LTD, with the registration number of SIN16120P.
This product contains Aripiprazole 1.0 mg/ml in the form of SOLUTION. It is approved for ORAL use.
This product is manufactured by Korea Otsuka Pharmaceutical Co. in KOREA, and Ltd. in REPUBLIC OF.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
Aripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.
Indication
For the treatment of schizophrenia and related psychotic disorders.
Mechanism of Action
Aripiprazole's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.
Active Ingredient/Synonyms
Abilitat | Aripiprazol | Aripiprazole | Aripiprazolum | OPC 31 | Aripiprazole |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.